Keywords: UK, NICE, Alzheimer's, Pfizer, Eisai, Aricept, Shire, Reminyl, Novartis, Exelon, Lunbeck, Ebixa, Bayer, Nexavar, Scotland, SMC

Final appraisal from UK’s NICE backs improved treatment access for early Alzheimer’s disease; SMC negative for Nexavar

Article | 18 January 2011

Print This

The UK’s National Institute for Health and Clinical Excellence (NICE) today published its final appraisal determination containing final ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in